verapamil has been researched along with saquinavir in 40 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (12.50) | 18.2507 |
2000's | 17 (42.50) | 29.6817 |
2010's | 17 (42.50) | 24.3611 |
2020's | 1 (2.50) | 2.80 |
Authors | Studies |
---|---|
Dintaman, JM; Kim, AE; Silverman, JA; Waddell, DS | 1 |
Cvetkovic, M; Fromm, MF; Kim, RB; Leake, B; Wilkinson, GR | 1 |
Back, DJ; Eagling, VA; Profit, L | 2 |
Choo, EF; Imamura, H; Kim, RB; Leake, B; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
Daily, JP; Fahey, JM; Greenblatt, DJ; Perloff, MD; von Moltke, LL | 1 |
Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A | 1 |
Thakker, DR; Troutman, MD | 1 |
Collett, A; Hallifax, D; Tanianis-Hughes, J; Warhurst, G | 1 |
Dansette, PM; Fontana, E; Poli, SM | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
Antonsson, M; Bengtsson, O; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Jerndal, G; Wan, H; Winiwarter, S | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Basilico, N; Bernetti, M; Bonache de Marcos, MC; Brogi, S; Brun, R; Butini, S; Caccia, S; Camodeca, C; Campiani, G; Gemma, S; Gorelli, B; Guiso, G; Joshi, BP; Lamponi, S; Martin, RE; Moretti, V; Novellino, E; Parapini, S; Rottmann, M; Sanna Coccone, S; Saponara, S; Savini, L; Summers, RL; Taramelli, D | 1 |
Bartolommei, G; Basilico, N; Brindisi, M; Brogi, S; Butini, S; Camodeca, C; Campiani, G; Fiorini, I; Gabellieri, E; Gemma, S; Gualdani, R; Habluetzel, A; Kukreja, G; Kunjir, S; Lamponi, S; Lucantoni, L; Martin, RE; Moncelli, MR; Novellino, E; Savini, L; Summers, RL; Tadini-Buoninsegni, F; Taramelli, D; Valoti, M | 1 |
Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Artursson, P; Mateus, A; Matsson, P | 1 |
Balcazar, DE; Bellera, CL; Bruno-Blanch, LE; Carrillo, C; Casassa, AF; Gálvez, J; Gavernet, L; Labriola, CA; Palestro, PH; Romano, PS; Talevi, A; Vanrell, MC | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Esaki, T; Kawashima, H; Komura, H; Kuroda, M; Mizuguchi, K; Natsume-Kitatani, Y; Ohashi, R; Watanabe, R | 1 |
Alex, R; Alsenz, J; Steffen, H | 1 |
Cauda, R; Leone, G; Lucia, MB; Rutella, S | 1 |
Honda, Y; Koyabu, N; Kuwano, M; Morimoto, S; Ohtani, H; Sawada, Y; Shoyama, Y; Uchiumi, T; Ushigome, F | 1 |
Griffin, BT; O'Driscoll, CM | 1 |
Balimane, PV; Chong, S; Marino, A | 1 |
Cataldo, A; Déglon, J; Mangin, P; Staub, C; Thomas, A | 1 |
Kataoka, M; Masaoka, Y; Sakuma, S; Yamashita, S; Yokoyama, T | 1 |
3 review(s) available for verapamil and saquinavir
Article | Year |
---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
37 other study(ies) available for verapamil and saquinavir
Article | Year |
---|---|
Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein.
Topics: 3T3 Cells; Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Survival; Cyclosporine; HIV Protease Inhibitors; Mice; Rhodamine 123; Rhodamines; Saquinavir | 1998 |
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Topics: Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Carrier Proteins; Genes, MDR; HeLa Cells; Histamine H1 Antagonists; Humans; LLC-PK1 Cells; Mice; Rats; Swine; Terfenadine; Tissue Distribution; Transfection; Vaccinia virus | 1999 |
Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Beverages; Caco-2 Cells; Citrus; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Gas Chromatography-Mass Spectrometry; HIV Protease Inhibitors; Humans; In Vitro Techniques; Ketoconazole; Liver; Mixed Function Oxygenases; Plant Extracts; Saquinavir; Time Factors; Verapamil | 1999 |
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Brain; Caco-2 Cells; Dibenzocycloheptenes; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Male; Mice; Quinolines; Testis | 2000 |
Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cell Line, Transformed; Colonic Neoplasms; Drug Resistance, Multiple; Furans; Gene Expression Regulation, Neoplastic; HIV Protease Inhibitors; Humans; Indinavir; Ivermectin; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Tumor Cells, Cultured; Verapamil; Vinblastine | 2000 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine | 2003 |
Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blotting, Western; Cells, Cultured; Diffusion; Humans; Intestinal Absorption; Intestinal Mucosa; Models, Biological; Permeability; Pharmaceutical Preparations; Pharmacokinetics | 2003 |
Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport, Active; Caco-2 Cells; Cell Membrane Permeability; Humans; Intestinal Absorption; Mice; Mice, Knockout; Pharmacokinetics; Spectrometry, Mass, Electrospray Ionization | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
Topics: Animals; Blood-Brain Barrier; Brain; Extracellular Fluid; Humans; Linear Models; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.
Topics: Aminoquinolines; Animals; Antimalarials; Biological Transport; Cell Line; Chloroquine; Clotrimazole; Drug Resistance; Female; Half-Life; Hemeproteins; Humans; Malaria; Male; Membrane Transport Proteins; Mice; Models, Molecular; Mutation; Oocytes; Piperazines; Plasmodium berghei; Plasmodium falciparum; Protozoan Proteins; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Ventricular Pressure; Xenopus laevis | 2012 |
Mimicking the intramolecular hydrogen bond: synthesis, biological evaluation, and molecular modeling of benzoxazines and quinazolines as potential antimalarial agents.
Topics: Animals; Antimalarials; Benzoxazines; Cell Line; Humans; Hydrogen Bonding; Magnetic Resonance Spectroscopy; Mice; Models, Molecular; Molecular Mimicry; Quinazolines; Spectrometry, Mass, Electrospray Ionization | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
Topics: Animals; Clofazimine; Cysteine Endopeptidases; Dihydropyridines; Drug Repositioning; Female; Male; Mice; Molecular Docking Simulation; Protein Conformation; Protozoan Proteins; Saquinavir; Trypanocidal Agents; Trypanosoma cruzi | 2015 |
Development of an
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Cell Line; Computer Simulation; Endothelial Cells; Gene Knockout Techniques; Humans; Organic Chemicals; Rats, Transgenic | 2021 |
Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Biological Transport; Caco-2 Cells; Calcium Channel Blockers; Cyclosporine; HIV Protease Inhibitors; Humans; Immunosuppressive Agents; Intestinal Absorption; Ritonavir; Saquinavir; Verapamil; Vinblastine | 1998 |
Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Flow Cytometry; Fluorescent Dyes; HIV Protease Inhibitors; Humans; Indinavir; Lymphocytes; Nelfinavir; Rhodamine 123; Ritonavir; Saquinavir; Temperature; Verapamil | 1999 |
HIV protease inhibitors reduce IL-2 release from normal human phytohaemagglutinin-activated T cells.
Topics: Calcium Channel Blockers; HIV Protease Inhibitors; Humans; Indinavir; Interleukin-2; Lymphocyte Activation; Mitogens; Phytohemagglutinins; Ritonavir; Saquinavir; T-Lymphocytes; Verapamil | 2001 |
Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.
Topics: Algorithms; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Beverages; Biological Transport, Active; Caco-2 Cells; Calcium Channel Blockers; Citrus; Cyclosporine; Food-Drug Interactions; HIV Protease Inhibitors; Humans; Immunosuppressive Agents; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Plant Extracts; Propionates; Quinolines; Saquinavir; Transfection; Verapamil; Vinblastine | 2004 |
An examination of the effect of intestinal first pass extraction on intestinal lymphatic transport of saquinavir in the rat.
Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Biological Transport, Active; Cyclosporine; Cytochrome P-450 Enzyme System; Data Interpretation, Statistical; Intestinal Absorption; Ketoconazole; Lymphatic System; Male; Micelles; Rats; Rats, Wistar; Saquinavir; Triglycerides; Triolein; Verapamil | 2008 |
P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate?
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cell Line, Tumor; Cell Membrane Permeability; Digoxin; Drug Evaluation, Preclinical; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Propionates; Quinolines; Saquinavir; Verapamil | 2008 |
On-line desorption of dried blood spot: A novel approach for the direct LC/MS analysis of micro-whole blood samples.
Topics: Adsorption; Anti-HIV Agents; Blood Chemical Analysis; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Humans; Mass Spectrometry; Online Systems; Reference Standards; Reproducibility of Results; Saquinavir; Solvents; Verapamil | 2009 |
Estimation of P-glycoprotein-mediated efflux in the oral absorption of P-gp substrate drugs from simultaneous analysis of drug dissolution and permeation.
Topics: Algorithms; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Drug Interactions; Erythromycin; Gene Expression; Glycerol; Humans; Intestinal Absorption; Loperamide; Models, Biological; Pharmaceutical Preparations; Propanolamines; Puromycin; Quinidine; Saquinavir; Solubility; Surface-Active Agents; Terfenadine; Verapamil; Vinblastine | 2011 |